and Jody everyone. Thanks good afternoon
product quarter higher and second for sales from financial Our to the in reflect equity our resulting results product investments. change strategy
release this of with will maximize associated based competition call is the in performance around disappointed going Later is the down in to remaining rights real forward. to assets, business Depomed Thursday, our diabetes generic upon as you positive acquired Tekturna licensed strategy Anchen. million. and Dominic type impairment seen shareholders but by sales our last transaction United value rate future States rather additional $XX we the we with an II aliskiren all press by the product and for will attractive we Noden which of a for haven't case details write quarter, recent issued by uncertainty are a royalties on and begin discussing indication In Noden the our Depomed this our highly of see on of give payable with of I PDL with not While return. of the
royalty covered $XXX the split. to products the agreement Slide flows XR than Synjardy original and this Depomed. of October Turning a million times $XXX of cash amendment of licensed evenly generic, Under purchased rather its flows or diabetes Glumetza $XXX as will XR. this with additional two would Products amended XXX% XXXX, royalties Upon agreement. XX/XX by million our and we royalties and X. for transaction the type XXX% amount receive we announced Depomed, in the II now by last until as announced authorized and million of Invokamet agreement mark week, Under million mark, XR, our reached beyond include the than sales on Jentadueto original split $XXX.X well our PDL cash agreement we reaching milestones to
than into this is mark October entered originally $XXX projection the reach by XXXX, anticipated sooner current to the at Our we million much had time agreement. we
investments, executing from for compelling away focus our we and reasons it. strategic transaction this While is product had on equity a shift
to-date. with this familiarity on had asset great assets was First, we with second our decision and based success the Depomed have our
into background agreement are million in As XXXX, mark projected $XXX we October we the reaching on original entering the XXXX.
expectations. our from agreement that exceeding of ahead with We flows timing this are cash well
on as In XXXX. fact, of June XX, flows as see X $XXX eclipsed million Slide you can cash cumulative
and equity focus to seek is strategic value continue pharmaceuticals. companies Pharma we through we the and two focus have LENSAR stated, completed a on additional past primary As and Noden transactions In our and equity create shareholder with product products previously investments. to years, with long-term primary
are opportunities model the followed we to criteria. that into opportunities. first strategy, our We thorough strict identified categories. business Opportunities product fit in actively our On fit by under general acquisition review that three strategy very fall betting selection a
commercial access performance financial whose stage management First from our and expertise. product benefit for can companies, to resources
appreciation growing Or structure final for approval. current and products assets continue of the positive stage pharmaceutical divestiture the existing ITL cash asset. We value of synergies strategy, of cash products to in in we our offer business execute a then robust expect by operating flows is balance, data with our a operational that PDL have standalone from The Biopharma or profitable through Second, and to to To generating flows look maximize needs the we returns cash streams. or market regulatory acquired assets, invest underappreciated. to long-term we These increase awaiting share that include or or then will underestimated our III value. with which shareholder have Phase believe step additional entities. nurturing are future provide with in goal companies as revenue third, royalty our these our value capture attractive companies and excess funds late
Slide to X. Turning
million over to in which this include first million through collected of expected years months estimate in we of million are have five We $XX to are the These cash of assets. XXXX, over cash be our the we our have next of six part exceed royalty and asset rights $XX cumulatively year will $XXX for XXXX. estimate outlined that year's basis by million from we rights. XXXX the They values flows of royalty these the a north cash flows generating $XXX in to
for years extend XXXX. past flows cash meaningful many Additional
to path We consummate in deals our and products on businesses attractive expertise are and to could confident acquired success. the
deal several of some pipeline underway stages while of multiple near-term, round with a additional negotiations have process. are which parallel, building We evaluation We currently are including actively in candidates in our new discussions. promising evaluating also opportunities of in the earlier our second
either terms interest us unacceptable terminated the conducted recently by declining due or of as have in diligence. opportunity because we several We discussions
screening multiple We have in also opportunities the process. early
shareholder us beyond to acquisitions strategic appropriate value updates. afford increasing for least Our strong at opportunities sheet provide some balance and
repurchased common cash as We for we a pursue shares repurchase based way create have maximizing Board a value, current program of open our focus to on decision PDL the in while valuation. assets market to stock investing shareholders flow the also in made our stock on
have million subsequent share we to in in a early we completed In million repurchase, XXXX, share $XX now repurchase addition XXXX. program the $XX completed
consider acquiring future repurchase will products. of opportunity those or with Board businesses Our and authorizations balances
price impairment to our and in reduction assets the $X.XX to the the by X, Turning share, QX, book XXXX while in resulted in $X.XX. Slide intangible of to there reduced PDL to Noden if value continues per Even asset a $X.XX our and that will as we continue and between successfully book for our disconnect supports programs. Board's be strategy, our a this on this decision execute value our the gap stock to addressed. be remain confident share corporate We repurchase
and benefit shareholders to to would the Our the our that, strategic medium and Company With long-term. change like I Dominique in will over in Monnet. direction turn call
